what changed for me between month 9 and month 14
The title is the whole question — what changed for me between month 9 and month 14 — but here is why I am asking.
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Corrections welcome, especially the pedantic ones. Pedantry is how this board earns its reputation.
best — the order this archive was captured in
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.
This. Complementary mechanisms rather than more of the same is the actual argument for the pairing.
This.
This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.